PMW3 COVERAGE OF SILDENAFIL CITRATE BY EMPLOYERS AND HEALTH PLANS: LOWER THAN EXPECTED PHARMACY BENEFIT COSTS AND ADDITIONAL HEALTH BENEFITS  by Lehman, G & Duttagupta, S
267Abstracts
that switched to another SSRI ($169/patient/month) and
the group that discontinued SSRIs ($335/patient/month).
Sensitivity analyses demonstrated that the physician 
(specialist) visit was the single most important cost 
component (range, $100–$760) in this hypothetical 
population.
CONCLUSION: Sildenaﬁl can be a cost-effective add-on
therapy to control SSRI-induced ED. Healthcare payers
should consider this when developing optimum treatment
strategies for men with depression.
PMW3
COVERAGE OF SILDENAFIL CITRATE BY
EMPLOYERS AND HEALTH PLANS: LOWER
THAN EXPECTED PHARMACY BENEFIT COSTS
AND ADDITIONAL HEALTH BENEFITS
Lehman G1, Duttagupta S2
1National Business Coalition on Health, Washington, DC,
USA; 2Pﬁzer Pharmaceuticals Group, Pﬁzer Inc, New York,
NY, USA
OBJECTIVES: The approval of sildenaﬁl citrate as the
ﬁrst effective oral therapy for the treatment of erectile
dysfunction (ED) was met with both anticipation of 
its potential beneﬁts and concern regarding its potential
costs to employers and health plans. Health plan execu-
tives and employer healthcare professionals were asked
to determine what effect adding sildenaﬁl to pharmacy
formularies had on pharmacy beneﬁt costs.
METHODS: Utilizing their own pharmacy and medical
claims data, a panel of health plan executives and
employer healthcare professionals determined the actual
cost increase incurred as well as other effects of adding
coverage of sildenaﬁl to pharmacy beneﬁts. Per member
per month (PMPM) cost was calculated as total cost to
the plan divided by total membership distributed over 12
months.
RESULTS: Panel members included three executives from
health plans with 93,000 to 15 million members and 5
wellness and beneﬁts specialists and corporate medical
directors from companies employing 6000 to 150,000
employees. Actual PMPM costs associated with sildenaﬁl
addition to pharmacy formularies were $0.04, $0.05 or
less, $0.09, and $0.21. Many of the companies sponsored
men’s health screening and educational programs in 
conjunction with introduction of sildenaﬁl coverage.
Adding sildenaﬁl coverage and increasing the focus on
men’s health was associated with an increased use of the
healthcare system by men resulting in earlier detection
and treatment of underlying conditions that may con-
tribute to ED including hypertension, diabetes, ischemic
heart disease, dyslipidemia, depression, and prostate
cancer.
CONCLUSIONS: Although estimates as high as $1
PMPM were predicted, actual costs of sildenaﬁl coverage
were $0.05 PMPM or less at several companies. Addi-
tionally, assessment of ED provided an important oppor-
tunity for physicians to screen their patients for other,
potentially serious medical conditions that otherwise may
have gone undetected. This earlier disease detection may
be associated with less expensive treatment and better
outcome.
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OBJECTIVE: Numerous models have attempted to cal-
culate the cost effectiveness (CE) of HRT in peri- and
post-menopausal women. These models have used differ-
ent methods, structure, assumptions and inputs. Conse-
quently they have produced varying results, which can
impede decision makers’ ability to clearly understand the
value of HRT. We developed standard evaluation scenar-
ios to control for cross-study variations in model struc-
ture, major assumptions and inputs in order to better
understand the CE of HRT.
METHODS: We evaluated 12 original models published
between 1980 and 2001 and reporting net cost per
LY/QALY saved. Eight standard scenarios, deﬁned using
age at initiation (<60 or >=60 years of age), duration of
therapy (<10 or >=10 years), and inclusion of breast
cancer and coronary heart disease (CHD), were compiled
to facilitate this evaluation. The data collected were then
analyzed within and across scenarios to detect common
trends in results.
RESULTS: When the only beneﬁt considered in the 
analysis was fracture prevention, the economic value of
HRT was dependent on the length and age of initiation
of therapy. CE was most favorable when HRT was 
initiated later in life and for long-term (>10 years)
therapy. Analyses including CHD beneﬁts considerably
improved the CE ratios of HRT, regardless of age of 
initiation and duration of therapy.
CONCLUSIONS: Though some trends were identiﬁed
with this method, we found the lack of consistency in
methodology and inputs among the analyses did not
provide a comprehensive evaluation of the economic
value of HRT. Speciﬁcally, previous studies rarely
included HRT’s impact on menopausal symptoms, and no
studies distinguished between the impacts of different
HRT agents, which vary in terms of compliance and 
tolerability. Inclusions of these issues will likely affect 
the CE ratios, especially for younger postmenopausal
women. Therefore, these inputs should be included in
future economic analyses.
